LoQus23 Therapeutics Ltd

LoQus23 Therapeutics Ltd is a biotechnology company based in Cambridge, founded in 2019.

The company focuses on developing oral small molecule inhibitors aimed at halting somatic expansion, which is a key factor in Huntington’s Disease and other triplet repeat expansion disorders. Their mission is to address DNA instability to slow or stop neurodegeneration in these diseases. The company’s lead drug candidate, LQT-23, is a first-in-class oral medication designed to slow or stop the progression of Huntington’s Disease. It is expected to enter clinical trials in 2026. LoQus23 also targets conditions like Myotonic Dystrophy Type 1 and other related disorders. With a strong foundation in research and development, the company collaborates with academic and research institutions to enhance understanding of these diseases and advance therapeutic options.